Search Results

Home → Flash News → Unlock the full potential of the Dr. GPCR platform by updating your profile 🧬 Find like-minded scientists, and colleagues who work on the same topic as you 🙌 ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile #gpcr #drgpcr Published on January 22, 2025 Category Dr. GPCR Profiles Unlock the full potential of the Dr. GPCR platform by updating your profile 🧬 Find like-minded scientists, and colleagues who work on the same topic as you 🙌 ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile #gpcr #drgpcr Previous Next Recent Articles

Founded in 2020, Dr. GPCR unites researchers, industry, and partners to accelerate GPCR science and drug discovery—through connection, education, and real‑world collaboration. About Dr. GPCR Ecosystem We unite the GPCR community to advance drug discovery. We bring the GPCR community together to fuel GPCR drug discovery—one receptor at a time. Our goal is to deepen our understanding of GPCR function and accelerate the development of better therapies together. Founded in 2020, Dr. GPCR was created to break down barriers across academia, biotech, pharma, and CROs—so knowledge, tools, and talent can flow where they’re needed most. Contact Us Our Mission Advance GPCR science and drug discovery by connecting people, data, and opportunities across the global GPCR ecosystem. Our Vision A world where GPCR insights translate quickly into real‑world therapies through an open, trusted, and collaborative community. What We Do (in Three Verbs) Connect — Researchers, founders, students, and industry partners meet, learn, and collaborate. Educate — Courses, talks, and curated content that turn expertise into execution. Accelerate — Intros, resources, and visibility that move projects and careers forward. Who Should Join To join the community, you should be actively related to the GPCR field , including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma founders/operators CRO/technology providers serving GPCR programs Clinicians and translational teams Investors and BD professionals focused on GPCRs Eligibility: We verify GPCR relevance during onboarding to preserve focus and quality. Partner With Us Build visibility, trust, and feedback directly from your target audience. Partner perks: Direct interaction with researchers, founders, and decision‑makers Access to all member perks for your entire team Product & service listings in ecosystem directories Speaking, demo, and content opportunities Input into community programming and field priorities CTA: Contact us to partner Our Values Scientific Rigor — Evidence first; hype last Openness with Intent — Share to accelerate; respect boundaries Diversity & Inclusion — More perspectives → better science Member‑First — We build what the community needs Execution — Ideas become results through consistent cadence Meet The Team Founder & Director Yamina Berchiche Get in touch Co-Founder Attila Foris Get in touch Board Member Anne M. Quinn Get in touch Board Member JoAnn Trejo Get in touch Board Member Maria Waldhoer Get in touch Chief Matchmaker Mark Schmeizl Get in touch

Home → Flash News → Do you remember the first time you were left alone in the lab with an experiment? 🤔 Did your experience compare to Dr. Brian Hudson’s? 😄 Tune into this week’s Dr. GPCR Podcast for great stories, GPCR insights, and a fascinating journey that led Dr. Hudson to years of groundbreaking research at the University of Glasgow. Don’t miss out! ✅Listen now https://buff.ly/aEQGUFl #gpcr #drgpcr Published on March 17, 2025 Category Dr. GPCR Podcast Do you remember the first time you were left alone in the lab with an experiment? 🤔 Did your experience compare to Dr. Brian Hudson’s? 😄 Tune into this week’s Dr. GPCR Podcast for great stories, GPCR insights, and a fascinating journey that led Dr. Hudson to years of groundbreaking research at the University of Glasgow. Don’t miss out! ✅Listen now https://buff.ly/aEQGUFl #gpcr #drgpcr Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session II AGPCR signaling pathways and trafficking Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Localization of putative ligands for adhesion G protein-coupled receptors in mouse tissues. Yuling Feng Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Shen,Tingzhen; Bernadyn,Tyler; Kwarcinski, Frank; Gandhi, Riya; Tall, Greg. University of Michigan." About Yuling Feng "I am currently a postdoctoral research fellow working with aGPCR pharmacology and physiology in rodents." Yuling Feng on the web LinkedIn The ADGRF5/GPR116 receptor is a key regulator of lymphatic endothelial cell identity and function Monserrat Avila Zozaya Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Serafin D. Stephen, Caron Kathleen M Department of Cell Biology and Physiology at UNC Chapel Hill 111 Mason Farm Road, MBRB, CB 7545. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 27599" About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing (GAIN) domain of Latrophilin 3 receptor under the mentorship of Dr. Antony Boucard. I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic endothelial cells (LECs), a cellular model with unique junction arrangements where aGPCRs are mainly unexplored. " Monserrat Avila Zozaya on the web LinkedIn Caron Lab Antony Boucard Lab Dr. GPCR Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity and augment survival in medulloblastoma. Erwin G. Van Meir Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Yamamoto, Takahiro 1,2*, De Araujo Farias, Virginea 1, Zhu, Dan3; Kuranaga, Yuki1, Parag, Rashed Rezwan 1,4,, Osuka, Satoru1,5 1 Department of Neurosurgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2 Department of Neurosurgery, Kumamoto University, Kumamoto, Japan 3 Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA 4 Graduate Biomedical Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA " About Erwin G. Van Meir "Dr. Erwin Van Meir is a professor in the UAB Department of Neurosurgery. He was trained in molecular biology at the Universities of Fribourg and Lausanne, Switzerland where he obtained his Ph.D. in 1989. Dr. Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined the faculty of Emory University in 1998. His research interest lies in understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics that will improve patient survival. Van Meir’s research examines how genetic alterations and hypoxia induce changes in cell biology that promote tumor formation with particular emphasis on adhesion GPCRs ADGRB1 and ADGRB3. Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor pathway and the epigenetic reader MBD2 (methyl CpG binding protein 2). His research aims to translate these novel agents to testing in clinical trials with the hope to develop novel medicines for cancer treatment." Erwin G. Van Meir on the web Google Scholar Site Specific N-Glycosylation Of The N-Terminal Fragment Of ADGRG6 Drives Proteolytic Processing, Trafficking And Signalling Pal Kasturi Abstract "ADGRG6 is a member of the adhesion G-protein-coupled receptor (aGPCR) family, known to play a role in myelination, placentation, blood vessel, and inner ear development. Like many other aGPCRs, ADGRG6 undergoes autoproteolysis at the GPCR-autoproteolysis site (GPS) enclosed within the larger GAIN domain to generate the N-terminal (NTF) and C-terminal fragments (CTF). These cleaved fragments join to form the heteromeric ADGRG6 receptor complex. ADGRG6 NTF has multiple extracellular domains like CUB, PTX, SEA, hormone binding domain, and the GAIN domain, which regulate G-protein signaling by binding to extracellular matrix proteins and mechanotransduction. The short stachel sequence at the extreme N-terminal end of the CTF functions as a tethered agonist to activate cAMP signaling. GPCR signaling and trafficking can be regulated by several different post-translational modifications (PTM). Stehlik et al. have reported that ADGRG6 expressed in lipopolysaccharide stimulated human umbilical vein endothelial cells is N-glycosylated. However, it is unclear which domains of ADGRG6 are N-glycosylated and how this might affect the overall molecular pharmacology of the receptor. Furthermore, are there spatial roles of N-glycosylation in ADGRG6 processing, trafficking, signalling and in-vivo functions? To address these gaps in knowledge, we used biochemical and cell-biological approaches using cell-lines overexpressing wild-type and N-glycosylation mutants of ADGRG6. We observed that N-glycosylation specifically takes place in the NTF and not the CTF of ADGRG6. Our results demonstrate that specific N-glycan residues in different domains of the extracellular NTF of ADGRG6 have distinct roles in ADGRG6 autoproteolysis, furin cleavage, membrane trafficking, and G-protein signalling. In the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development using zebrafish models." Authors & Affiliations "Anandhu Jayaraman: Department of Biology, Ashoka University Prabakaran Annadurai: Department of Biology, Ashoka University. Currently: University of Leipzig Mansi Tiwari: Department of Biology, Ashoka University. Currently: University of Aberdeen Priyadatha Sajan: Department of Biology, Ashoka University, Currently: University of Groningen Nayonika Chatterjee: Department of Biology, Ashoka University Prateek Sibal: Department of Biology, Ashoka University" About Pal Kasturi "I received my bachelor’s degree in Physiology from Presidency College, University of Calcutta and went on to complete my masters from Madurai Kamaraj University. During my PhD training, I worked in the laboratory of Dr. Kathryn Defea at the University of California, Riverside. For my PhD thesis, I worked on non-canonical, scaffold driven signaling by protease activated receptor-2 (PAR2). I joined University of Texas Southwestern Medical Center, for my postdoctoral training. Here, I worked on the regulation of the Sonic Hedgehog pathway by GPCRs which localized to the primary cilia. I then joined the laboratory of Dr. Velia Fowler, at the Scripps Research Institute, as a Judith Graham Poole postdoctoral fellow to work on the role of cytoskeletal proteins in megakaryocyte to platelet differentiation. I joined the Department of Biology at Ashoka University in 2020 as an assistant professor." Pal Kasturi on the web Ashoka University < Previous Session Next Session >

How Michelle Halls turned an unexpected summer project into a GPCR research career redefining spatial signaling and drug discovery. Home → Flash News → How GPCR Spatial Signaling Sparked a Scientific Journey How GPCR Spatial Signaling Sparked a Scientific Journey Published on November 12, 2025 Category Dr. GPCR Podcast When boredom met obsession. It started as a summer project.A reluctant student pipetting through the day, expecting nothing more than routine lab work. But for Michelle Halls, that first experiment flipped everything. One spark led to a PhD at Monash University, a fellowship at University of Cambridge, and eventually a leadership role at the forefront of GPCR spatial signaling — a field reshaping how we understand receptor biology and drug discovery. Michelle’s story isn’t just about science.It’s about what happens when curiosity takes over. From reluctant intern to scientific leader From local signaling to spatial pharmacology From spark to strategy Read the full story here🔗 https://www.ecosystem.drgpcr.com/post/how-gpcr-spatial-signaling-sparked-a-scientific-journey 🔓 Want deeper GPCR insights? Join Dr. GPCR Premium for exclusive content, expert access, and community. #GPCR #DrGPCR #SpatialSignaling #Pharmacology #DrugDiscovery #ScientificLeadership #Biotech Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma Date & Time Friday, November 3rd / 4:20 PM About Victoria Rasmussen "Victoria Rasmussen is a graduate fellow in Dr. Thomas Sakmar’s laboratory at Rockefeller University, where she studies the signaling and degradation of G protein-coupled receptors. She completed her undergraduate education at Providence College, receiving a B.S. in Biology and a B.A. in Psychology. During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods of synthesizing 2-imidazoline scaffolds to be used as proteasome modulators in the laboratory of Travis Bethel. Victoria started her Ph.D. at the Tri-Institutional Ph.D. program in Chemical Biology, where she joined the lab of Thomas Sakmar at Rockefeller University. She is currently working to understand the signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic strategy. " Victoria Rasmussen on the web Tri-Institutional PhD Program Chemical Biology LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Vaithish Velazhahan About Vaithish Velazhahan Vaithish obtained dual bachelor’s degrees with honors in Medical Biochemistry and Microbiology from Kansas State University, USA. His undergraduate thesis work on studying the biochemical mechanisms of flavonoids in cancer using nuclear magnetic resonance spectroscopy (NMR) led to a Barry M. Goldwater Scholarship. He then received a prestigious Gates Cambridge Scholarship to study for a Ph.D. at the MRC Laboratory of Molecular Biology and the University of Cambridge, where he is currently a final year Ph.D. candidate. His Ph.D. work has been focused on understanding the structure and activation of Class D fungal GPCRs. He has developed novel tools and methodologies to study fungal GPCRs which allowed the determination of the first structures of the prototypical fungal GPCR Ste2. This work has led to two first-authored manuscripts published in the journal Nature. Vaithish has been recognized with the MRC LMB's Max Perutz Prize for outstanding Ph.D. work and has been elected a Research Fellow at Gonville and Caius College, which is one of the most prestigious positions at the University of Cambridge. Vaithish Velazhahan on the web Twitter GatesCambridge PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Strategic Project Management for scientists Dr. Yamina Berchiche Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Yamina Berchiche

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. Learn more. Dr. GPCR Summit We live in a new world, and we think it's an opportunity to try new things and use current technologies to help us connect and spread scientific advances in the GPCR field. Our goal is to allow everyone in the GPCR community to get access to the talks through the entire length of the event independently of their time zone. This means that presenters will have the option of providing a pre-recorded talk or giving a live presentation. More information is outlined below. See Schedule See Schedule See Schedule

<< Back to podcast list Strategic Partner(s) Dr. John Streicher About this episode Our guest in this episode of the Dr.GPCR podcast is Dr. John Streicher from the department of pharmacology at the University of Arizona. John started grad school in 1999 and spent some time figuring out what he was interested in. It turns out that it was signal transduction, and he worked on the signaling cascades involved in heart failure. His encounter and interest in signaling in the context of GPCRs during his postdoctoral training in Dr. Laura Bohn’s lab at Scripps Research Institute in Florida. Today, John and his team focus on understanding how signal transduction cascades downstream of the opioid receptors work, including the unique organization of chaperone protein Hsp90 modulation of opioid signaling in the brain versus the spinal cord. Dr. John Streicher on the web University of Arizona Department of Pharmacology Google Scholar Pubmed LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Genetic Deletion of Atypical VGLUT3 Rescues Huntington’s Disease Phenotype and Neurodegeneration in zQ175 Mice Date & Time Friday, November 3rd / 2:10 PM About Karim Ibrahim "A postdoctoral researcher, interested in studying G-protein coupled receptors and their role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases." Karim Ibrahim on the web X (Twitter) Google Scholar Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session IX / Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane targets, such as ion channels, remains a significant challenge. Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome these obstacles by producing high-quality antibodies that more accurately mimic natural protein structures. This approach contrasts with other antigen forms like peptides or DNA, which face limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody discovery. Several case studies of GPCR and other multi-pass transmembrane targets are presented, including GPRC5D, Claudin 6 and Napi2b. These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity compared to other methods. These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug resistance and tumor escape. About Gavin Zhang Gavin is a currently a director of business and operations at Novoprotein Scientific. His research experience includes phylogenetics and cancer epigenetics. Gavin Zhang on the web LinkedIn < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Graeme Milligan About Dr. Graeme Milligan Professor Graeme Milligan is Gardiner Professor of Biochemistry, Dean of Research, and Deputy Head of the College of Medical, Veterinary, and Life Sciences at the University of Glasgow. His main research group centers on the function, structure, and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins. His experience also includes translating knowledge generated into the selection of targets, screening, and identification of small molecule regulators of these proteins, and progressing such ligands in drug development programs. Prof. Milligan has published more than 550 peer-reviewed articles and his research has been cited more than 35,000 times. He was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016. Prof. Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria. Dr. Graeme Milligan on the web University of Glasgow ResearchGate PubMed Orcid Google Scholar LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Robert F. Bruns About Dr. Robert F. Bruns Fred Bruns discovered the first positive allosteric modulator (PAM) of a GPCR in the late 1980s while working at Warner-Lambert/Parke-Davis. The work was published in 1990. After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced through Phase 2 clinical trials. Fred obtained an A.B. in Psychology from Washington University in St. Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego. His doctoral dissertation was the first large-scale study of structure-activity relationships for adenosine receptors. During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay. He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor, A2a and A2b. In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab. He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 switched to computational chemistry full-time. He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical candidate in 2013. Dr. Bruns has over 80 publications and 11,000 citations, with an h-index of 47. Dr. Robert F. Bruns on the web ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Developing new tools to uncover GPCR signaling patterns with Remi Janicot About Remi Janicot I was born in Paris (France) and grew up in Europe until I was 18. After graduating high school, I moved to America to pursue my passion for basketball while continuing high level studies. I played collegiate basketball and earned my bachelor’s at Ursinus College, a small school around Philadelphia where I graduated from in 2018. After that, I worked at Johns Hopkins in Baltimore as a research assistant investigating mechanisms and treatments for pediatric epilepsy. With my background in neuroscience, the lab of Dr. Mikel Garcia-Marcos seemed like a good fit as GPCRs are integral to the functioning of the nervous system (and much more). My particular projects revolve around developing new tools to study GPCR activity in ways that were not previously possible. This research has led to a first-author Cell article on the development of a new biosensor platform called ONE-GO biosensors. Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect GPCR/G protein signaling which I would be happy to discuss. Remi Janicot on the web Chobanian & Avedisian School of Medicine Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Welcoming Remarks < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Tobi Langenhan About Dr. Tobi Langenhan "I studied medicine at the University of Würzburg, where I obtained my license to practice and my Dr. med. degree in neuroanatomy. Then I moved to the University of Oxford on a 4-year Wellcome Trust Scholarship in Neuroscience, through which I gained an M.Sc. from Somerville College and a D.Phil. from Magdalen College Oxford, both in Neuroscience. For my doctoral studies, I joined the lab of Dr Andreas Russ at the Department of Biochemistry and first came across GPCRs, particularly the receptor family I have been investigating ever since: adhesion GPCRs. After returning to Germany I set up my own lab at the Institute of Physiology at Würzburg, where I later became Heisenberg Professor for 'Physiology and pathophysiology of mechanoceptive signalling pathways'. Shortly after was recruited to the Medical Faculty of Leipzig University, where I now head the Department of General Biochemistry at the Rudolf Schönheimer Institute. I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart the physiological and pharmacological principles that underlie the workings of adhesion GPCRs in health and disease. This entails the deciphering of cellular and organ functions, which require individual adhesion GPCRs, and extends to the development of novel screening approaches to identify pharmacological modulators of human adhesion GPCRs." Dr. Tobi Langenhan on the web Langenhan Lab ORCID LinkedIn University of Leipzig Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Discover the evolution of GPCR research — from single pipettes to automated platforms shaping precision, strategy, and leadership in modern science. Home → Flash News → From Pipettes to Platforms The Evolution of GPCR Research From Pipettes to Platforms: The Evolution of GPCR Research Published on November 13, 2025 Category Dr. GPCR Podcast Back when GPCR assays were performed with single channel pipettes, failure wasn’t cheap. Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive. Today, automation and high-throughput platforms make it easy to forget how fragile discovery used to be. But that history matters. It shaped how we design experiments, make decisions, and lead teams. In this week’s Dr. GPCR Podcast blog, we unpack: How the manual era shaped experimental discipline Why technology changed what we ask, not just how we ask How scientists grow from technicians to strategic leaders 🎧 Read the full story and listen to the episode: https://www.ecosystem.drgpcr.com/post/from-pipettes-to-platforms-the-evolution-of-gpcr-research 🔓 Join Dr. GPCR Premium for deeper tools and insights: https://www.ecosystem.drgpcr.com/gpcr-university-pricing #GPCR #DrGPCR #DrugDiscovery #Pharmacology #Biotech Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda State of the Art Talk Adhesion GPCR in Mechanobiology Abstract Only Available for AGPCR24 Attendees About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc . Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Bryan Roth About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Your complete guide to AGPCR24. Inside, you’ll find the schedule, speaker bios, venue map, travel tips, and essential information to make the most of your workshop experience. OFFICIAL BOOKLET Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF You can also download the booklet by scanning this QR code

The Practical Assessment of Signaling Bias Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Home → Flash News → 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles ✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 8, 2025 Category Dr. GPCR Courses 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics✅ PK-PD Modeling – Predicting drug behavior, non-linear PK✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi About Dr. Nagarajan Vaidehi "Nagarajan Vaidehi, Ph.D., is professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research Institute of the City of Hope in Los Angeles, CA. She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi received her Ph.D. in quantum chemistry from the Indian Institute of Technology in India, where she was honored with the Distinguished Alumni Award in 2016. Following her postdoctoral studies on protein dynamics simulation methods at University of Southern California, and at Caltech, she became the director of biomolecular simulations at the Materials and Process Simulation Center, Beckman Institute at Caltech. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair of DCQM in 2018. She has advanced the use of computational methods to meet the challenges of designing therapeutics with lower off target effects. She is an internationally recognized biophysicist for her contributions in developing constrained molecular dynamics simulation methods with emphasis on application to G-protein coupled receptors and drug design." Dr. Nagarajan Vaidehi on the web City of Hope Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

A breakthrough in GPCR imaging reveals a full native pancreatic islet and advances how GLP-1R can be visualized in tissue using chemical probes. Home → Flash News → Lighting up a native pancreatic islet isn’t just a technical win it’s a shift in what GPCR imaging can reveal Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal Published on December 8, 2025 Category Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery Previous Next Recent Articles

Home → Flash News → Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Published on April 22, 2025 Category Dr. GPCR Podcast Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Previous Next Recent Articles

Home → Flash News → Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. Published on December 12, 2024 Category GPCR Weekly News Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. ➡ https:// www.ecosystem.drgpcr.com/gpcr-binders-drugs-and-more/design-of-allosteric-modulators-that-change-gpcr-g-protein-subtype-selectivity #gpcr #drgpcr Previous Next Recent Articles

A failed experiment led Dr. Jens Carlsson to his true calling—computational biochemistry. Discover how embracing failure turned frustration into a breakthrough career designing GPCR experiments before they happen. 🎧 Listen to his story on the Dr. GPCR Podcast. Home → Flash News → ep 175 with jens carlsson release picture Model. Predict. Discover. – Podcast Episode Release Published on October 22, 2025 Category Dr. GPCR Podcast What if a failed experiment became the best thing that ever happened to your career? Dr. Jens Carlsson started his journey aiming to be a biotech engineer. But during a summer internship in protein purification, he faced a harsh reality: lab work wasn’t his strength. The experiments didn’t work, the data didn’t flow, and it was frustrating. But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why things weren’t working. A professor noticed and called it out in a recommendation letter. That unexpected moment of clarity redirected his path. Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based modeling to predict GPCR-ligand interactions, before they’re ever tested in the lab. The mindset shift? Stop explaining experiments after they happen. Start designing them to happen. His journey is a powerful reminder that the right career often reveals itself through “failure.” Follow what lights you up. Notice where your mind naturally goes. And don’t ignore the signs, it might be your real path calling. 🎧 Listen to Jens’ full story on the Dr. GPCR Podcast : https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover #DrGPCR #GPCR #CareerInScience #ComputationalBiology #DrugDiscovery #PhDLife Previous Next Recent Articles

A conversation with Prof. David Hodson on visualizing GLP-1 and GIP receptors in pancreatic islets and brain circuits to advance GPCR-targeted therapies for diabetes and obesity. << Back to podcast list Strategic Partner(s) Visualizing GLP-1 & GIP Receptors in Islets and Brain In this episode, Professor David Hodson discusses how GLP-1 and GIP receptors regulate metabolism across the pancreas and brain, and why visualizing receptor localization and signaling in real tissues is essential for advancing GPCR drug discovery . His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and ligand engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic design. The conversation also highlights the role of interdisciplinary collaboration in accelerating innovation in diabetes and obesity research. Why this matters How receptor distribution in islets and brain circuits shapes incretin hormone drug effects Why visualization tools changed our understanding of GPCR signaling in metabolic tissues What collaborative chemistry enabled in designing receptor-targeted fluorescent ligands The moment when structural and imaging evidence clarified unexpected glucagon-derived peptide behavior How future metabolic therapies may evolve based on receptor cross-talk and tissue-specific engagement Who should listen Navigated complex datasets where interpretation depended on biological context Balanced innovation with the need for reproducible, well-controlled functional assays Worked across disciplines where chemistry, pharmacology, and physiology converge Questioned how drug action differs in real tissues vs. recombinant cell lines …this episode will resonate. About David Hodson Prof. David Hodson is the Robert Turner Professor of Diabetic Medicine at the University of Oxford , working within the Oxford Centre for Diabetes, Endocrinology and Metabolism. Originally trained as a Veterinary Surgeon , he completed postdoctoral research at the CNRS in Montpellier before establishing his independent laboratory at Imperial College London as a Diabetes UK RD Lawrence Fellow. He later served as Professor of Cellular Metabolism and Institute Deputy Director at the University of Birmingham. His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within complex tissues, with direct relevance to type 2 diabetes and obesity therapy . David Hodson on the Web Radcliffe Department of Medicine Islet Biology Lab University of Birmingham Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. Learn more. Meet Dr. GPCR Summit Partners - Click to Explore - Dr. GPCR Summit 2021 Welcome to the official page of the Dr. GPCR Virtual Summit 2021! << Live talk schedule >> << Pre-recorded talk list >> The program is complete! Don't miss a chance to listen to 25+ scientific talks, which will only be available for those who registered during the Summit. Get your All-Access ticket before they're gone by visiting Eventbrite today! Got your All-Access ticket already? Special shout out to our partners! Check your inbox this week, you'll be able to invite a friend or colleague to join the Summit for Free! Proceeds from the ticket sales will be used to provide the best three trainee talks with fantastic prizes, including a personalized autographed copy of Dr. Lefkowitz's biography. Present a pre-recorded talk and get free access to the entire Summit! Hurry, the deadline to submit your talk is Friday, September 10th, 2021, at midnight EST. If you're facing financial difficulties or are a trainee who would like to attend but can't submit a pre-recorded talk, reaches out to us now! The live talks will be held on Zoom, and everyone who registered will be able to ask their questions to the speakers all week on Microsoft Teams! You'll also be able to meet our partners on Microsoft Teams. Make sure you have a profile picture set for both Zoom and Microsoft Teams! Everyone is welcome to present their work (students, postdocs, PI's, biotech, pharma companies)! There are no posters! All pre-recorded talks will be available during the summit for free with registration. All live talks will have a $5 attendance fee/ talk You can get full access to all the talks for $100 For Speakers Step 1: Let us know that you'd like to present your work by filling out this short form here Step 2: Prepare your video abstract and your presentation (pre-recorded or live)* Step 3: Click here to send us your pre-recorded presentation or click here*** to submit the information to your live presentation before August 5th, 2021. ***All live talks are now scheduled Please provide us with your pre-recorded presentation by September 10th, 2021 *Note: Scroll down to find resources to help you prepare your video presentation, and don't hesitate to get in touch if you need help. Contact us at Hello@DrGPCR.com Some housekeeping items first We strongly suggest you carefully consider what type of information you share in your presentation. We will do our best to keep the Summit a closed event, but Dr.GPCR is not responsible for any loss of intellectual property. How will I access the talks during the Summit? You will receive an email from Eventbrite containing the relevant information before the summit. Be sure to register. How can I sponsor the 2021 Summit? Please visit our Sponsor Page to learn more about sponsorship opportunities to sponsor the Summit and the DrGPCR Ecosystem. For more information, please email us at Hello@DrGPCR.com In what form can I submit my abstract? Abstract submission can be in the form of classical text abstract or in the form of a short (max. 3 minutes) video. This is an excellent opportunity to be as creative as you want to be. We recommend writing a 200-300 word abstract, giving you enough information to provide a great video abstract in under 3 minutes. How will I present my talk? You can pre-record your talk. We recommend submitting pre-recorded talks. What does this mean? You send us the video of your full-length talk, and we will take care of the rest. Alternatively, you can provide us with the embed code to make your presentation available during the Summit. Pros: You can polish your recording to your satisfaction. Anyone can watch it from anywhere, even multiple times. Imagine binge-watching your favorite talk over and over whenever you want to during the Summit. Cons: It may take more time to record an excellent presentation, but nothing is impossible! Click here to submit your pre-recorded presentation. Can I present a live talk or event? How? In case you'd like to present a talk live, we'll help with it. Pros: It may take less time to prepare for the presentation Cons: You may make mistakes since it's a live event, and if you decide to keep your talk live only, participants can watch it only once. *Tip Become a DR. GPCR Member by creating your own personalized page. Read more about becoming a member here . If you need help preparing your pre-recorded video and video abstract check out these resources: How to record your talk in PowerPoint 365 How to record your talk using a previous PowerPoint version How to record your talk using Keynote on a Mac Do you have any questions? Email us at Hello@DrGPCR.com << Live talk schedule >> << Pre-recorded talk list >> Meet Dr. GPCR Summit Partners - Click to Explore - Tags Dr. GPCR Summit Dr. GPCR Summit 2021 Dr. GPCR Summit 2021 Pre-Recorded Talks Dr. GPCR Summit 2021 Live Talks